Orion invests an annual average of about 15% of its net sales in research and product development, a work field of about 600 people.

The focus in Orion’s pharmaceutical R&D is on early research, i.e. preclinical as well as clinical Phases I and II, whereas the large-scale Phase III trials are preferred to be conducted together with partners selected for further development and marketing. Research is increasingly done in collaboration with other pharmaceutical companies also in the early phases of R&D with an aim to develop new, innovative medicinal treatment approaches for unmet medical needs.

Read more in the particular sub pages dealing with Orion’s R&D.